美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Silver Standard Resources Inc

9.56

0.0000

成交量：- -

成交額：- -

市值：11.42億

市盈率：16.48

高：9.56

開：9.56

低：9.56

收：9.56

52周最高：15.84

52周最低：7.70

股本：1.19億

流通股本：8,050.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.5800

淨資產收益率：--

總資產收益率：--

市淨率：1.24

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

綠葉製藥：若欣林治療廣泛性焦慮障礙的中國Ⅲ期臨牀試驗完成所有患者入組

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SSRI"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SSRI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSRI\",,,,,undefined,":{"symbol":"SSRI","market":"US","secType":"STK","nameCN":"Silver Standard Resources Inc","latestPrice":9.56,"timestamp":1502136000000,"preClose":9.56,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":80500000,"shares":119488000,"eps":0.58,"marketStatus":"退市","change":0,"latestTime":"08-07 16:00:00 EDT","open":9.56,"high":9.56,"low":9.56,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.58,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.56,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSRI\",,,,,undefined,":{"symbol":"SSRI","floatShares":80500000,"roa":"--","roe":"--","lyrEps":0,"shares":119488000,"dividePrice":0,"high":9.56,"amplitude":0,"preClose":9.56,"low":9.56,"week52Low":7.7,"pbRate":"1.24","week52High":15.84,"institutionHeld":0.5011,"latestPrice":9.56,"eps":0.58,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.58,"open":9.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSRI\",params:#limit:5,,,undefined,":[{"date":"2017-08-03","symbol":"SSRI","newSymbol":"SSRM","type":"symbolChange","dateTimestamp":1501732800000},{"market":"US","date":"2017-05-03","symbol":"SSRI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1493784000000,"reportTimeType":"post","actualEps":0.17},{"market":"US","date":"2017-02-23","symbol":"SSRI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1487826000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-11-08","symbol":"SSRI","fiscalQuarterEnding":null,"expectedEps":0.18,"name":null,"time":"盤後","type":"earning","dateTimestamp":1478581200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-08-10","symbol":"SSRI","fiscalQuarterEnding":null,"expectedEps":0.14,"name":null,"time":"盤後","type":"earning","dateTimestamp":1470801600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSRI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSRI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSRI\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2560079979","title":"綠葉製藥：若欣林治療廣泛性焦慮障礙的中國Ⅲ期臨牀試驗完成所有患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2560079979","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560079979?lang=zh_tw&edition=fundamental","pubTime":"2025-08-18 12:34","pubTimestamp":1755491640,"startTime":"0","endTime":"0","summary":"格隆汇8月18日丨绿叶制药宣布，集团自主研发的1类创新药若欣林用于治疗广泛性焦虑障碍的Ⅲ期临床试验已完成所有患者入组。该项Ⅲ期临床试验为一项多中心、随机、双盲、安慰剂对照的研究，以评估若欣林治疗广泛性焦虑障碍的安全性和有效性。若欣林是中国首个自主研发并拥有自主知识产权，用于治疗抑郁症的化药1类创新药，自2022年在中国获批上市以来，其治疗抑郁症的疗效和安全性不断获得临床认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250818123607974e6101&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250818123607974e6101&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","BK4092","SSRI","NE","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE0002270589.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SSRI\",params:#limit:6,delay:false,,,undefined,":[]}}